Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Calyx IPO test India investors’ appetite for CRAMS

This article was originally published in Scrip

Executive Summary

Just a few days after Arch Pharmalabs announced its initial public offering on the Indian stock market (scripintelligence.com, 31 March 2011), a second contract research and manufacturing services (CRAMS) firm, Calyx Chemicals and Pharmaceuticals has announced its own plans for an initial public offering (IPO). The uptake of newly issued Arch and Calyx stock will test investor enthusiasm for service offerings in the Indian pharmaceutical sector.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC012469

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel